Aktiebolaget Hässle v Alphapharm Pty Limited

Link copied
Case Copied 78 min read

FEDERAL COURT OF AUSTRALIA
Aktiebolaget Hässle v Alphapharm Pty Limited [2000] FCA 1303

AKTIEBOLAGET HÄSSLE and ASTRA PHARMACEUTICALS PTY LIMITED v ALPHAPHARM PTY LIMITED

N 670 of 1999

WILCOX, MERKEL & EMMETT JJ
9 OCTOBER 2000
SYDNEY

IN THE FEDERAL COURT OF AUSTRALIA

NEW SOUTH WALES DISTRICT REGISTRY

N670 of 1999

BETWEEN:

AKTIEBOLAGET HÄSSLE
First Appellant

ASTRA PHARMACEUTICALS PTY LIMITED
Second Appellant

AND:

ALPHAPHARM PTY LIMITED
Respondent

JUDGES:

WILCOX, MERKEL AND EMMETT JJ

DATE:

9 OCTOBER 2000

WHERE MADE:

SYDNEY

CORRIGENDA

From the above judgment handed down in Sydney on 9 October, 2000 by Justices Wilcox, Emmett and Merkel JJ please note the following:

.at para 75, line 1, between the words “accepted” and “the proposition”, delete the word “of”;

.at para 144, line 14, replace the word “approval”, which appears in the phrase “Dr Brown’s erroneous approval”, with the word “approach”; and

.on the final page, replace the date of judgment and of certification, originally noted as 12 October 2000, with the date “9 October 2000”.

Donna Bowman
Associate for Justice Wilcox

Dated:             24 October 2000


FEDERAL COURT OF AUSTRALIA
Aktiebolaget Hässle v Alphapharm Pty Limited [2000] FCA 1303

PATENTS  - Combination patent for drug formulation – validity of patent – whether patent lacked an inventive step – whether combination obvious.

Patents Act 1990, ss 7(2), 18(1)(b)

AKTIEBOLAGET HÄSSLE and ASTRA PHARMACEUTICALS PTY LIMITED
v ALPHAPHARM PTY LIMITED

N 670 of 1999

WILCOX, MERKEL & EMMETT JJ
9 OCTOBER 2000
SYDNEY


IN THE FEDERAL COURT OF AUSTRALIA

NEW SOUTH WALES DISTRICT REGISTRY

N 670 of 1999

BETWEEN:

AKTIEBOLAGET HÄSSLE
First Appellant

ASTRA PHARMACEUTICALS PTY LIMITED
(ACN 009 682 311)
Second Appellant

AND:

ALPHAPHARM PTY LIMITED
(ACN 002 359 739)
Respondent

JUDGES:

WILCOX, MERKEL AND EMMETT JJ

DATE OF ORDER:

9 OCTOBER 2000

WHERE MADE:

SYDNEY

THE COURT ORDERS THAT:

1.The appeal be dismissed.

2.The appellants, Aktiebolaget Hässle and Astra Pharmaceuticals Pty Limited, pay the costs of the respondent, Alphapharm Pty Limited.

Note:    Settlement and entry of orders is dealt with in Order 36 of the Federal Court Rules.


IN THE FEDERAL COURT OF AUSTRALIA

NEW SOUTH WALES DISTRICT REGISTRY

N 670 of 1999

BETWEEN:

AKTIEBOLAGET HÄSSLE
First Appellant

ASTRA PHARMACEUTICALS PTY LIMITED
Second Appellant

AND:

ALPHAPHARM PTY LIMITED
Respondent

JUDGES:

WILCOX, MERKEL AND EMMETT JJ

DATE:

9 OCTOBER 2000

PLACE:

SYDNEY

REASONS FOR JUDGMENT

EMMETT J:

  1. The Court: The first appellant, Aktiebolaget Hässle, a Swedish corporation, is registered as the patentee of Australian Patent Number 601974 (“the Formulation Patent”).  The second appellant, Astra Pharmaceuticals Pty Limited, an Australian company, is related to the first appellant and isthe exclusive licensee in Australia of the Formulation Patent. in Australia. Both appellants are members of the Astra pharmaceuticals group whose head office is in Sweden.  As nothing turns on the identity of particular companies in the group, itIt is convenient to refer to both appellants, and tothe group to which they belong, as “Astra”.  The respondent, Alphapharm Pty Limited (“Alphapharm”), is an Australian company that…

CaseChat AU logo

Keep reading for free

Create a free CaseChat account to read Aktiebolaget Hässle v Alphapharm Pty Limited and more:

  • Read every judgment in full
  • Ask AI and get answers linked to paragraphs
  • See how each paragraph was cited in later cases
  • Download judgments as PDF or Word
Continue with Google

One click creates your free account or signs you in.

By continuing you agree to the Terms and Privacy Policy.

Details
Case
[2000] FCA 1303
Decision Date

CaseChat Overview and Summary

Aktiebolaget Hässle and Astra Pharmaceuticals Pty Limited appealed against a decision that their patent was invalid for lack of an inventive step. The Court of Appeal held that the patent, which related to an oral formulation for the delivery of the drug omeprazole, was valid. The dispute centred on whether the claimed formulation involved an inventive step given the common general knowledge in the field of pharmacology at the relevant priority date. The Court found that while some aspects of the formulation were obvious, the use of a subcoating layer was not. This layer was soluble or rapidly disintegrating in water, or consisted of polymeric, water-soluble, film-forming compounds. The Court held that it was not obvious to use such a subcoating layer within the formulation described in the patent. The evidence indicated that it was not immediately apparent to those in the field that such a subcoating layer would be effective or necessary.

The Court of Appeal addressed the key legal issue of whether the claimed formulation involved an inventive step. The Court noted that for a patent to be valid, it must involve some degree of inventiveness, but this could be small. The Court applied the test of whether the invention would have been obvious to a non-inventive skilled worker in the field, equipped with the common general knowledge as at the priority date. The Court held that while the use of an enteric coating and the core material comprising omeprazole and an alkaline reacting compound or salt were obvious, the use of a subcoating layer was not. The Court found that the evidence showed that it was not obvious to those in the field that such a subcoating layer would be effective or necessary. The Court rejected the argument that the combination of the claimed elements was obvious from the outset.

The Court of Appeal held that the patent was valid as it involved an inventive step in the use of a subcoating layer within the formulation described in the patent. The Court held that the appeal should be dismissed and that the appellants should pay the costs of the respondent. The Court found that the claimed formulation did not involve an inventive step as a whole, but that the use of the subcoating layer was not obvious and thus contributed to the inventiveness of the formulation. The Court rejected the argument that the finding of the primary judge that the combination claimed in the patent was not obvious at the outset logically concluded the issue of obviousness in favour of the appellants.

Orders

Orders of the court

1. The appeal be dismissed.

2. The appellants, Aktiebolaget Hässle and Astra Pharmaceuticals Pty Limited, pay the costs of the respondent, Alphapharm Pty Limited.

Background

Background to the litigation

Aktiebolaget Hässle and Astra Pharmaceuticals Pty Limited (appellants) brought an appeal against the decision of Lehane J which found that the patents in question were obvious and lacked an inventive step. The patents in question relate to a pharmaceutical formulation of omeprazole, an acid-labile compound used to treat gastrointestinal diseases. The formulation comprises a core material of omeprazole and an alkaline reacting compound or alkaline salt, a subcoating layer soluble or rapidly disintegrating in water or consisting of polymeric, water-soluble, film-forming compounds, and an enteric coated outer layer. The dispute centred around whether it was obvious for a hypothetical formulator to include the subcoating layer, and if so, whether it was obvious to use a subcoating layer as described in the patent.

The matter initially came before Lehane J in the Federal Court of Australia, who found that the patents were obvious and lacked an inventive step. The appellants then appealed to the Full Court of the Federal Court, arguing that the primary judge erred in finding that the invention was obvious. The Full Court considered the evidence and arguments presented by both parties and reviewed the relevant legal principles.

Evidence

Evidence Before The Court

In analysing the evidence, it is necessary for us to bear in mind that the step that is claimed to be inventive was the selection of the integers; none of the integers, itself, is claimed to be inventive. The patent identifies three integers:· core material comprising omeprazole and an alkaline reacting compound or alkaline salt;·a subcoating layer soluble, or rapidly disintegrating, in water or consisting of polymeric, water soluble, film forming compounds; and·an enteric coated outer layer. As to the first integer, omeprazole is a “given”; the whole purpose of the formulation was to deliver that particular drug to the bloodstream of a patient. The basic information would instruct the hypothetical formulator that omeprazole is an acid-labile compound. It follows, as was generally agreed at the trial, that it would immediately be apparent to the hypothetical formulator that the omeprazole would need to be stabilised by association with an alkaline reacting compound or alkaline salt. The first integer selects itself. We do not understand there to be any dispute about that proposition. Nor do we understand there to be any dispute about the obviousness of using an enteric coating. An enteric coating is a coating that is resistant to acids. Given that omeprazole is acid-labile, and the known presence of acid gastric juices in the stomach, an enteric coating is an obvious requirement for delivering a satisfactory quantity of omeprazole to the small intestine. It is notable that all the expert witnesses thought the first step for the hypothetical formulator was to apply an enteric coating directly to the core material and test the result. The evidence of Dr Pilbrant established that this was the first step in fact taken by the Astra team. As the trial judge commented, in para 94 of his reasons: “At the outset, the formulator would have had no reason to suppose that a simple enteric coated dosage form would not suffice.” The only integer whose presence raises a doubt about obviousness is the subcoat. Was it obvious, within the sense of the relevant legal authorities, for the hypothetical formulator to try out the idea of a subcoat? And, if so, was it obvious for the hypothetical formulator to try out a subcoat falling within the description contained in the patent? These are the questions critical to the claim of lack of inventive step. They overlap and may be addressed together. Before going to the evidence pertaining to these issues, we indicate that we reject the submission made by counsel for Astra that the finding made by Lehane J, in para 110 of his reasons for judgment (quoted at para 48 above), logically concluded the issue of obviousness in their clients’ favour. It will be recalled that his Honour said that “considered at the commencement of a hypothetical attempt … the combination claimed in the patent was not obvious” (our emphasis). That finding would dispose of the issue only if the concept of obviousness was restricted, in the case of a combination patent, to a situation where the hypothetical formulator could foresee, at the commencement of his or her task and without the necessity for testing or any process of trial and error, which particular integers (out of all those “worth a try”) would be most appropriate. However, that is not the law, as was made clear by Buckley LJ in the extract from the Beecham Group quoted at para 36 above. Once it is accepted that it is sufficient that it be obvious to the hypothetical formulator that a particular possibility is worth trying (perhaps amongst many possibilities), it must follow that it is incorrect to say that an invention lacks obviousness simply because the hypothetical formulator would, or might, have been unable to say in advance which (if any) of the possibilities worth trying would prove most satisfactory.

Decision

Reasons for decision

Issues
1. Was it obvious for the hypothetical formulator to try out the idea of a subcoat in the pharmaceutical formulation?
2. Was it obvious for the hypothetical formulator to try out a subcoat falling within the description contained in the patent?
3. Are Claims 13, 14, 15, 16, and 17 entirely dependent on Claim 1 for the purposes of considering the question of inventive step?

Held
1. It was not obvious for the hypothetical formulator to try out the idea of a subcoat in the pharmaceutical formulation, as it was uncertain whether such a subcoat would be beneficial or even necessary.
2. It was obvious for the hypothetical formulator to try out a subcoat falling within the description contained in the patent, as it was within the realm of possibilities worth exploring.
3. Claims 13, 14, 15, 16, and 17 are not entirely dependent on Claim 1 for the purposes of considering the question of inventive step, as no distinction was suggested between Claim 1 and the other claims.

Ratio Decidendi

Legal Principle Established

Claims 13, 14 and 15 are concerned with the preparation of an oral formulation. Claims 16 and 17 are concerned with methods in “the treatment of gastrointestinal disease”. Although Claims 13, 15, 16 and 17 are not, in terms, entirely dependent on Claim 1, there has been no suggestion that any distinction should be drawn between Claim 1 and any of the other claims for the purposes of considering the question of inventive step. Accordingly, it is not necessary at this stage to deal with the detail of any of those other claims. Tthe law as to “inventive step” The inventive element needed to sustain a patent may be small. A “scintilla of inventiveness” is sufficient; “no smallness or simplicity will prevent a patent being good”: see – Meyers Taylor Pty Ltd v Vicarr Industries Ltd (1977) 137 CLR 228 at 249. However, while While a simple idea may be inventive, it is nevertheless essential for the validity of a patent that there be some inventiveness. In Allsop Inc v Bintang Ltd (1989) 15 IPR 686 at 701, a Full Court of this Court adopted a statement made in the Supreme Court of the United States in Graham v John Deere Co of Kansas City (1966) 383 US 1 at 15: “the subject matter sought to be patented must be beyond the skill of the calling”. The Full Court also referred to a dictum of Cotton LJ in Britain v Hirsch (1888) 5 RPC 226:“I do not agree with the view … that when anything is done which has not been done before, that is sufficient to justify a patent being obtained for it. In my opinion, it must be a question of whether there is sufficient invention to justify a monopoly being granted by the Crown in the particular thing.” Section 100(1)(e) of the 1952 Act speaks of a patent being revoked where the invention is obvious and does not involve an inventive step “having regard to what was known or used in Australia” on or before the relevant priority date”. That which is obvious does not involve an inventive step. That which involves an inventive step is not obvious. That matter is to be judged against the background of what was known or used in Australia on or before the relevant priority date. The expression “what was known or used in Australia on or before the priority date” has been explained by reference to a line of authority that predated the 1952 Act. The test of what was obvious, and did not involve an inventive step, having regard to what was known or used in Australia at the priority date, isof whether the invention would have been obvious to a non-inventive skilled worker in the field, equipped with the common general knowledge in that particular field of endeavour as at the priority date. It cannot be assumed that common general knowledge in Australia is the same as common general knowledge in a place outside Australia. Itt is necessary to prove, by evidence in the particular case, in any case just what constitutes the state ofrelevant common general knowledge in Australia: see is Wellcome Foundation Ltd v V.R. Laboratories (Aust) Pty Ltd (1981) 148 CLR 262 at 270.34 Common general knowledge comprises that which is known to, or used by, those in the relevant field. Common general knowledge consists of the background knowledge and experience that is available to all (not merely particular individuals) in the relevant field, in considering the making of new products or improvements in old products. It must be treated as being used by an individual as a general body of knowledge: see – Minnesota Mining &and Manufacturing Co v Beiersdorf (Australia) Ltd (1980) 144 CLR 253 at 292. The issue in the present case